Methods of inhibiting chemokine binding to chemokine receptors

Details Methods of inhibiting chemokine binding to chemokine receptors Methods of inhibiting chemokine binding to chemokine receptors

2003-08-28

2009-02-10

Landsman, Robert (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C424S185100, C530S300000

Reexamination Certificate

active

07488717

ABSTRACT:
Novel peptides or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.

REFERENCES:
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 2003/0027751 (2003-02-01), Kovesdi et al.
patent: 2003/0166004 (2003-09-01), Gyuris et al.
patent: 2004/0171552 (2004-09-01), Peled et al.
patent: WO 02/061087 (2002-08-01), None
patent: WO 03/072599 (2003-04-01), None
Hay DWP et al. Interleukin-8 receptor antagonists in pulmonary diseases. Current Opinion in Pharmacology. 2001. vol. 1, pp. 242-247.
Mukaida N. et al. Interleukin-8 and other CXC chemokines. In The Cytokine Handbook. vol. 2, 4thEd. Thomson and Lotze Eds. Academic Press, 2003.
Burmer et al. “G Protein-Coupled Receptor (GPCR) Antigenic Peptide Seq Id No. 944”, Retrieved From EBI Database Accession No. ABP82271, 2003. Abstract.
Proudfoot et al. “The Strategy of Blocking the Chemokine System to Combat Disease”, Immunological Reviews, 177: 247-256, 2000. p. 253-255.
Hayashi et al. “Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From Binding to and Activating Human Blood Neutrophils 1”, The Journal of Immunology, 154: 814-824, 1995.
Misumi et al. “A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate From the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 in CCR5 as A Novel Human Immunodeficiency Virus Type 1 Vaccine”, Journal of Virology, 75(23): 11614-11620, 2001.
Misumi et al. “A Novel Cyclic Peptide Immunization Strategy for Preventing HIV-1/AIDS Infection and Progression”, The American Society for Biochemistry and Molecular Biology, p. 1-38, 2003.
Baggiolini et al. “CC Chemokines in Allergic Inflammation”, Immunology Today, 15(3): 127-133, 1994.
Cocchi et al. “Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8= T Cells”, Science, 270: 1811-1815, 1995.
Ma et al. “Impaired B-Lymphopoiesis, Myclopoiesis, and Derailed Cerebellar Neuron Migration in CXCR4- and SDF-1-Deficient Mice”, Proc. Natl. Acad. Sci. USA, 95: 9448-9453, 1998.
Müller et al. “Involvement of Chemokine Receptors in Breast Cancer Metastasis”, Nature, 410: 50-56, 2001.
Strieter et al. “The Functional Role of the ELR Motif in CXC Chemokine-Mediated Angiogenesis”, The Journal of Biological Chemistry, 270(45): 27348-27357, 1995.
Vaddi et al. “Regulation of Monocyte Integrin Expression by β-Family Chemokines”, The Journal of Immunology, 153: 4721-4732, 1994.

Affiliated with

Also associated with

Rating

Methods of inhibiting chemokine binding to chemokine receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of inhibiting chemokine binding to chemokine receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting chemokine binding to chemokine receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4079695